Naslov
JAK2 V617F mutation and the clinical features in myeloproliferative disorders

Autori
Radić Antolic, Margareta ; Boban, Ana ; Zadro, Renata ; Juričević, Mirjana ; Sučić, Mirna ; Bašić-Kinda, Sandra ; Labar, Boris

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of "Leukemia and Lymphoma 2007 : West and East Together" ; u: Leukemia Research 31 (2007) (S2) ; Poster Sessions, S65-S116, PO35 / Bennet, J.M. ; Hamblin, T.J. - : Elsevier, 2007, S80-S80

Skup
Leukemia and Lymphoma 2007 : West and East Together

Mjesto i datum
Dubrovnik, Hrvatska, 15.09.2007. - 19.09.2007

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
JAK2 V617F; myeloproliferative disorders

Sažetak
Myeloproliferative disorders share clinical and biological similarities that may be influenced by presence of recently discovered point mutation in JAK2 gene (JAK2 V617F). The aim of this study was to determine the correlation between JAK2 V617F mutation and the clinical features of patients with polycythemia vera (PV) and essential thrombocythemia (ET). The study included 36 patients with PV (PV group) and 38 patients with ET (ET group). The diagnosis was established according to the Polycythemia Vera Study Group criteria. The detection of JAK2 V617F was performed by allele specific PCR (Baxter et al., Lancet 2005) on DNA isolated from bone marrow cells or peripheral blood cells. JAK2 V617F positive and negative members of PV and ET groups were analyzed for peripheral blood counts and bone marrow aspiration. JAK2 V617F positive PV patients exhibited statistically significantly higher number of red blood cells, white blood cells and platelets when compared to PV patients negative for JAK2 V617F. No statistically significant difference was found in hemoglobin concentration and hematocrit value. In contrast, JAK2 V617F positive subjects of the ET group had statistically significantly increased number of red blood cells, hemoglobin concentration and hematocrit value, and no significant difference in platelet or white blood cell count. Bone marrow evaluation revealed that JAK2 V617F positive patients of the PV group had myeloid hyperplasia with the excess of eosinophils and platelet clumps, which is consistent with the findings of the peripheral blood analysis. On the contrary, bone marrow evaluation of the ET group did not reveal any significant differences between JAK2 V617F positive and negative patients. Overall our data suggest that JAK2 V617F mutation status could serve as a criterion to categorize both PV and ET patients into distinct subgroups. Further studies are needed to determine whether JAK2 V617F mutation status in myeloproliferative disorders should be used as a criterion for therapy approach.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

Napomena
Doi: 10.1016/S0145-2126(07)70383-1

POVEZANOST RADA